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Abstract
Objective To compare the cost effectiveness of
sildenafil and papaverine›phentolamine injections for
treating erectile dysfunction.
Design Cost utility analysis comparing treatment with
sildenafil (allowing a switch to injection therapy) and
treatment with papaverine›phentolamine (no switch
allowed). Costs and effects were estimated from the
societal perspective. Using time trade›off, a sample of
the general public (n = 169) valued health states
relating to erectile dysfunction. These values were
used to estimated health related quality of life by
converting the clinical outcomes of a trial into quality
adjusted life years (QALYs).
Participants 169 residents of Rotterdam.
Main outcome measures Cost per quality adjusted
life year.
Results Participants thought that erectile dysfunction
limits quality of life considerably: the mean utility gain
attributable to sildenafil is 0.11. Overall, treatment
with sildenafil gained more QALYs, but the total costs
were higher. The incremental cost effectiveness ratio
for the introduction of sildenafil was £3639 in the first
year and fell in following years. Doubling the
frequency of use of sildenafil almost doubled the cost
per additional QALY.
Conclusions Treatment with sildenafil is cost effective.
When considering funding sildenafil, healthcare
systems should take into account that the frequency of
use affects cost effectiveness.
Introduction
The registration of sildenafil has initiated debate about
the socioeconomic aspects of this treatment for erectile
dysfunction. Generally, governments are concerned
about the affordability of sildenafil.1 It is not known
whether sildenafil is cost effective. Although the clinical
effects of sildenafil have been proved, uncertainty
remains about the value of sildenafil to both patients
and society.
We performed an economic evaluation of sildenafil
according to the usual recommendations.2 We used
cost utility analysis, a form of cost effectiveness analysis
in which clinical outcomes are converted into quality
adjusted life years (QALYs) gained. Both costs and
effects were measured from the societal perspective.
This means that treatment outcomes were valued by
the general public and that all costs were considered—
that is, medical costs, costs of patients, and costs in
other sectors of society. Costs and effects were analysed
over five years.
Participants and methods
We compared the costs of treatment with sildenafil
with that of conventional treatment. Before the
introduction of sildenafil, injection therapy was the
treatment of choice for erectile dysfunction.1 Many
patients, however, were unwilling to receive injection
therapy and accordingly did not seek treatment. We
therefore assumed that injection therapy was accepted
by 10% of patients (Pfizer, Netherlands, personal com›
munication, 1998, based on market research). The
vasoactive substance was papaverine›phentolamine
and not alprostadil, which is more commonly used,
because papaverine›phentolamine is less expensive
and equally effective. Papaverine›phentolamine injec›
tions are reimbursed in the Netherlands, but no
decision has yet been taken about reimbursement for
sildenafil.
We estimated utility values for different states of
erectile dysfunction. These utilities were applied to the
clinical outcomes before and after treatment in a clini›
cal trial of sildenafil by Goldstein et al.3 We also
estimated the costs of two treatment scenarios for erec›
tile dysfunction and analysed these in a model
comprising the probabilities of successful treatment,
switching and discontinuation of treatment, and dura›
tion of successful treatment. A detailed description of
our methods to analyse costs and effects is available.4
Clinical effects
The study by Goldstein et al is the largest dose escala›
tion study reported.3 It was placebo controlled and the
patient population consisted of men with erectile
dysfunction due to various causes. Efficacy was assessed
with the international index of erectile function.5 This
instrument contains questions about the two primary
end points of erectile dysfunction treatment as defined
by the National Institutes of Health—that is, the ability
to penetrate and the ability to maintain an erection
sufficient for satisfactory sexual intercourse.6 These
end points were used in the trial. Both questions have
five response levels, so together they categorise the
patients into 25 (5×5) erectile dysfunction states. These
erectile dysfunction states were valued in a separate
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exercise (described below). The elicited utilities were
applied to the health states of the patients in the study
of Goldstein et al before and after treatment. The
difference between the mean utility before and after
treatment (controlled for placebo) is the mean gain in
utility. Use of disease specific instruments to calculate
QALYs is advocated by Brazier and Dixon7 and Drum›
mond et al.8
Because we used previously reported trial data, we
had to consider the limitations of these data for use in
economic evaluation. Firstly, the trial was designed on
an intention to treat basis,3 which meant that patients
for whom sildenafil had no or insufficient effect
remained in the trial. As we could not discriminate
between patients with a sufficient or an insufficient
response, we used the mean utility gain in the trial to
calculate the utility gain of sildenafil. Consequently, we
underestimated the utility gain in daily practice
because only the utility gain of the successfully treated
patients should be taken into account. Secondly, results
of the international index of erectile function were not
available for injection therapy, nor were any other data
that allowed calculation of QALYs. We conservatively
assumed that the utility gain of sildenafil and
papaverine›phentolamine injections would be the
same. Given the low acceptability of injection
therapy,9 10 this assumption probably overestimates the
benefits of injection therapy.
Determining utilities for erectile dysfunction states
From a randomly selected sample of 45 000 people
obtained from the Rotterdam telephone directory we
recruited 354 people to participate in the valuation
task. They were invited by telephone to attend a session
of health state valuation and were offered about £10
plus travel expenses. In order to avoid selection bias,
the invitation was made without referring to erectile
dysfunction. Participants were given the opportunity to
withdraw from the valuation sessions without financial
consequences after they were informed about the sub›
ject of the study.
Participants valued 24 erectile dysfunction states
on a scale from 0 to 1 using time trade›off.8 The 25th
state described normal erectile functioning and was set
at a value of 1.0. Time trade›off was measured relative
to the life expectancy of the subjects. Before the valua›
tion task, participants gained experience of the time
trade›off method using general health states as defined
by the EQ›5D questionnaire.11
Time trade›off responses were considered invalid if
the participant showed a lexicographic response for
the EQ›5D states, had too much missing data either on
erectile dysfunction or EQ›5D states, or clearly did not
understand the task. A lexicographic response mode
means that when a respondent is faced with an option
he or she will always choose one particular alternative,
no matter how favourable the other might be. Subjects
had to value the health states “for a person like your›
self.” This means, for example, that older people gave
values from their own perspective, and people without
a sexually active partner would take this into account
when performing the valuation task. The exception
was that women were asked to imagine being a man
with erectile dysfunction. Values are independent of
the sexual activity of the respondents because the
descriptions of erectile function referred to the relative
number of successful attempts at intercourse. For
example, a respondent might be asked the following:
“If during the past four weeks, your condition was such
that you were sometimes able to attain an erection, and
you were (almost) never able to maintain your erection,
how many years would you be willing to trade off to
restore your erectile function?” This also implies that
erectile function is valued the same in patients with dif›
ferent levels of sexual activity.
Because we had decided to obtain social valuations
we asked a sample of the general public to value the
clinical outcomes.8 12 The reasoning behind this
decision relates to issues of equity and medical ethics.13
Some authors, however, claim that healthy people rela›
tively similar to affected patients should value clinical
outcomes.14 We therefore explored whether erectile
dysfunction is valued differently in different subgroups.
We used multivariate analysis of variance to determine
whether age, sex, the availability of a partner, having
children, sexual activity, and sexual satisfaction
influenced the values of the general public.
Costs
All costs are expressed in 1999 British pounds
(£1 = 1.62 euro). We used 1999 data to determine the
Dutch cost prices. To determine the medical costs, we
estimated resource use—for example, consultations
and prescription charges (a lump sum charge to
refund pharmacy costs and medicines) and multiplied
the quantities by the unit prices. We estimated resource
use of sildenafil and papaverine›phentolamine injec›
tions on the basis of consensus statements on both
treatments.15 We refined this estimate by developing a
low, baseline, and high cost scenario on the basis of
clinical experience in two hospitals (University Medical
Centre St Radboud, Nijmegen and Hospital St Antoni›
ushove, Leidschendam). Costs outside the healthcare
sector and productivity costs were assumed to be negli›
gible.
The cost of sildenafil was based on observational
data from the first quarter that sildenafil was available
in the Netherlands.16 A general practitioner or
urologist determined the effective dose in an academic
or peripheral setting. An appropriate share of the costs
of supporting departments was reflected in the cost of
a visit to a urologist. The physician’s costs were
calculated on the basis of the estimated duration of an
outpatient visit. The analysis included all costs related
to the hospital, such as costs of salaries and supplies,
costs of supporting departments, and overhead costs.
Cost effectiveness
We compared two scenarios: treatment with sildenafil
and treatment with papaverine›phentolamine (figure).
In the sildenafil scenario, we allowed patients to switch
to papaverine›phentolamine injections, as these
injections may be effective in patients in whom sildena›
fil has failed. Since sildenafil has already become the
treatment of choice, although its cost is not reimbursed
in the Netherlands, patients are unlikely to switch from
injections to sildenafil. A switch was therefore not
allowed in the papaverine›phentolamine scenario.
We compared the sildenafil and papaverine›
phentolamine scenarios assuming use once a week.
The maximum recommended frequency of
papaverine›phentolamine injections is once a week,
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but use of sildenafil is not limited for medical reasons.
Nevertheless, we believe that the assumption was
appropriate as the utility values were elicited
independently of the frequency of intercourse. More›
over, the marginal utility gain of increasing intercourse
frequency from once to twice a week is unlikely to be as
high as the increase between never being able to have
intercourse and being able to have intercourse once a
week.
The cost effectiveness of the different scenarios was
analysed in a model comprising acceptability of
treatment, probability of successful treatment, switch›
ing or discontinuation of treatment, and the duration
of successful treatment. The patient flows in the model
were determined on the basis of secondary data—for
example, published clinical trials,9–20 Dutch observa›
tional data,16 and clinical experience in the two partici›
pating hospitals. We performed an incremental
analysis of the costs and effects of sildenafil compared
with papaverine›phentolamine. The results are pre›
sented as cost per QALY.
The acceptance rate of papaverine›phentolamine
treatment could have been influenced by the fact that
erectile dysfunction is no longer a taboo subject. In
fact, an acceptance rate of 70% has been suggested as
feasible.21 We therefore included this variable in a sen›
sitivity analysis. Other variables included in the
sensitivity analysis were resource use, values, effective›
ness of treatment, and frequency of use. We performed
univariate sensitivity analysis to determine which vari›
ables have the largest influence on the results. In the
multivariate sensitivity analysis we explored to what
extent results would change under a (unlikely) worst
case scenario.
Results
Respondents
A total of 184 subjects (52%) failed to attend the inter›
view sessions. This was probably because of extremely
bad weather at the time of interview, which made it dif›
ficult for participants to reach the university. One per›
son withdrew from the study after he was informed
about the subject. A sample of 169 subjects valued the
erectile dysfunction states; 89% (150) of the responses
were valid. Age ranged from 18 to 80 years (mean age
of 45.8 (SD 15.4) years). There were 81 men (54%) and
69 women, which is close to the sex distribution in the
general population.
Effects
In Goldstein et al’s study the international index of
erectile function among men receiving sildenafil rose
from 2.0 at baseline to 3.9 at end of treatment for abil›
ity to penetrate (placebo group 2.1 to 2.3) and from 1.5
to 3.6 for satisfactory sexual intercourse (placebo
group 1.6 to 1.8).3 Table 1 gives the mean utilities that
were elicited for the 24 erectile dysfunction states
described by these two questions. The utilities ranged
from 0.74 to 0.94. When these values are combined
with trial data, the mean utility increased from 0.807 at
baseline to 0.915 at end of treatment for men receiving
sildenafil and from 0.819 to 0.821 for men receiving
placebo. Therefore, the mean utility gain attributable to
sildenafil is 0.11.
We analysed whether the values of the general
public were influenced by age, sex, availability of a part›
ner, having children, sexual activity, and sexual satisfac›
tion. The only relation we found was that participants
with children considered erectile dysfunction less of a
problem than subjects without children. Since there
were no differences between the values of men and
women, we used averaged values in the QALY analysis.
More extensive description of this analysis is avail›
able.22
Costs
Tables 2 and 3 show the resource use and the costs
attributable to treatment of erectile dysfunction with
sildenafil or papaverine›phentolamine injections.
Papaverine›phentolamine is cheaper per dose, but it
has to be prescribed by an urologist and therefore has
higher initial costs (£484 versus £407 for sildenafil).
Sildenafil has higher running costs: yearly treatment
costs are £254 versus £233 for papaverine›
phentolamine. The higher initial costs of papaverine›
phentolamine are recovered after seven years.
Sildenafil scenario
Papaverine-phentolamine scenario
Sildenafil
100%
Effective
65%
No response
35%
No other treament
10.5%
phentolamine
24.5%
Papaverine-
Effective
12.25%
No response
12.25%
phentolamine
10%
Papaverine-
Effective
6.4%
No response
3.6%
No treatment
90%
Patient flow for scenarios of treatment of erectile dysfunction with sildenafil or
papaverine›phentolamine injections
Table 1 Mean (SD) utility values assigned by general public for erectile dysfunction (n=150)
Ability to maintain an
erection
Ability to attain an erection
Never Few times Sometimes Most times Always
Never 0.74 (0.18) 0.79 (0.17) 0.82 (0.17) 0.82 (0.15) 0.84 (0.17)
Few times 0.77 (0.18) 0.83 (0.16) 0.85 (0.16) 0.86 (0.15) 0.88 (0.16)
Sometimes 0.79 (0.16) 0.85 (0.14) 0.87 (0.14) 0.90 (0.13) 0.91 (0.13)
Most times 0.81 (0.17) 0.86 (0.15) 0.88 (0.14) 0.94 (0.12) 0.93 (0.13)
Always 0.82 (0.17) 0.87 (0.15) 0.91 (0.13) 0.94 (0.11) 1.00
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Cost effectiveness
Overall, sildenafil creates more benefits and more costs
because more patients are treated (figure). Therefore,
the main issue is whether the additional effects of silde›
nafil are worth the additional costs. This question is
addressed in the incremental analysis shown in table 4.
The incremental cost utility ratio of sildenafil
compared with papaverine›phentolamine is £3639 per
QALY in the first year, decreasing to £2630 per QALY
after five years.
Sensitivity analysis
The frequency of use influences the outcomes consid›
erably. Doubling the frequency of use of sildenafil
increases the cost per additional QALY by 45% in the
first year and 85% in each following year. The initial
costs are relatively high because the costs of
non›responders are added to the costs of responders.
Hence, the effect of the frequency of use on the cost
per additional QALY is moderated in the first year. In
the long term, however, the main cost driver with silde›
nafil is the drug.
Assuming a lower utility gain (0.08) than observed
in the valuation study, resulted in a 37.5% increase in
cost per additional QALY.4 Effectiveness and accept›
ability also influenced the results significantly. The cost
per additional QALY increased 38% with a lower
effectiveness of sildenafil (50%), but decreased (1%) in
each following year. Changes in acceptability had an
opposite effect: when acceptability of papaverine›
phentolamine injections is increased to 70%, the incre›
mental cost utility ratio is 25% lower in the first year,
but 10% higher from the second year onwards. Uncer›
tainty about resource use did not influence the
outcomes significantly; in the analysis of different cost
scenarios (based on the number of visits and duration
of visits), the high cost scenario increased the costs per
additional QALY by only 8%.
When the uncertainty of all variables is combined
into a worst case model (low utility gain and effective›
ness and high costs, dropout, and acceptability), the
incremental cost utility ratio is £9343 per QALY in the
first year(156% increase), and £4691 in each following
year(101% increase).
Discussion
The mean incremental cost utility ratio of sildenafil
compared with papaverine›phentolamine was £3639
per QALY in the first year and improved in the follow›
ing years. This cost utility ratio is generally favourable,
as suggested acceptable thresholds of cost utility vary
between £8000 and £25 000.23 24 Moreover, many
interventions with less favourable cost utility ratios are
currently being funded, such as breast cancer screening
(£5780 per QALY) and kidney transplantation (£4710
per QALY).25 Uncertainty in the data did not hamper
interpretation of the results: even in the worst case sce›
nario, the incremental cost utility ratio of £9343 could
be considered favourable. Our analysis therefore
suggests that the clinical effect is derived at reasonable
costs.
Table 2 Volumes of resource use for sildenafil and injection
treatment*
Resource Sildenafil Injection
General model:
Acceptability of treatment (%) 100 10
% treated by general practitioner 80 10
% treated by urologist 20 90
No of pills or injections a week 1 1
Establishing effective dose:
No of visits 3.8 3.7
Mean duration of visits (min) 8.5 10.3
No of prescriptions16 2.5 2.3
% discontinuing treatment9 10 17›20 35 36
% switching because of effectiveness 50 0
Remaining part of first year:
No of visits 2.0 2.0
Mean duration of visits (min) 7.5 7.5
No of prescriptions16 7.8 4.3
% discontinuing treatment (%) 10 14
Each following year:
No of visits 1.5 1.5
Mean duration of visits (min) 7.5 7.5
No of prescriptions16 9.5 5.2
% discontinuing treatment 5 5
*As far as possible estimations are supported by scientific publications. When
no scientific publications were available, estimations were derived from the
opinion of clinical experts in the two participating hospitals. Figures of
acceptability of treatment and proportion of patients treated by general
practitioner or urologist were provided by Pfizer (based on market research,
1998).
Table 3 Unit costs (£) of sildenafil and injection treatment
Units of resource use
Cost price
(without value
added tax)
Sildenafil tablet16 4.33*
Papaverine›phentolamine injection 3.55
Visit to general practitioner (<20 min) 10.32
Visit to urologist (weighted mean, university/ peripheral
hospitals)
1.29/min
plus16.80
Prescription rule (charge to refund pharmacy costs) 3.14
*The mean cost price per pill is based on the “effective dose distribution”
across the different strengths of sildenafil.
Table 4 Costs and effects of treatment with sildenafil and papaverine›phentolamine injection and difference between two treatments
Year
Successfully treated patients (%) Incremental cumulative
effects (QALY)
Incremental cumulative
costs (£)
Incremental cost utility
ratio (£/QALY)Sildenafil Injection
1 77.25 6.40 7.79 28 368 3639
2 69.53 5.50 14.84 44 773 3017
3 66.05 5.23 21.53 60 356 2803
4 62.75 4.97 27.88 75 161 2695
5 59.61 4.72 33.92 89 226 2630
∞* 2329
*In year N the incremental cost utility ratio is a function of the incremental cumulative costs divided by incremental cumulative effects over these N years. But if you
look at the cost utility ratios in the first and second year separately, you get an incremental cost utility ratio of £3639 per QALY in the first year and £2329 per QALY
in the second year. The incremental cost utility ratio is constant from the second year on: £2329 per QALY. So, in the long term, the influence of the first year
treatment costs is diminishing and the incremental cost utility ratio approaches £2329 per QALY.
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Validity of assumptions
We made several assumptions that could be viewed as
unfavourable to sildenafil. For instance, we underesti›
mated the effects by not including partner satisfaction
and we assumed the effects of oral and injection treat›
ment to be equal. Furthermore, we used a relatively low
rate of drop out for injection therapy, which results in a
more favourable cost effectiveness ratio for injection
therapy.9–20 Although such assumptions might intro›
duce bias, the interpretation of the results is not greatly
affected because the assumptions in the economic
appraisal of sildenafil were conservative.
The utility values we elicited for erectile dysfunc›
tion did not take into account possible comorbidity. As
in most cases total disutility is less than the sum of
parts,26 we might have overestimated the effect.
However, the sensitivity analysis showed that sildenafil
remained cost effective with lower utility gains.
The subjective nature of the value of erectile func›
tioning again raises issues about whose values should
be used in economic appraisal of health care: the
values of the general public or those of people at risk
(in our case ageing men). However, we found that the
utility values for sexual functioning were independent
of background variables such as age, sex, and sexual
activity. Therefore, neither the limitations in the repre›
sentativeness of our sample, nor our choice to elicit
values from the general public has influenced the
results.
Implications
These findings should be interpreted in the light of the
discussion about the affordability and value of sildena›
fil to society. Firstly, we have shown that erectile
dysfunction limits quality of life considerably, in the
eyes of the general public. Furthermore, our study
shows that sildenafil is cost effective, and its reimburse›
ment should therefore be considered. However, as fre›
quency of use greatly affects cost, such reimbursement
should not be unconditional.
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What is already known on this topic
Clinical research suggests that sildenafil is an
effective treatment for erectile dysfunction
Economic appraisal of sildenafil is needed given
the prevalence of the disorder and controversy
regarding funding of treatment
What this study adds
Erectile dysfunction is generally perceived as a
disease that limits quality of life considerably
The clinical effect of sildenafil is derived at
reasonable costs
Health service funding of sildenafil should be
considered
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